Ikena Oncology appoints Jotin Marango as CFO and Head of Corporate Development

ImageneBio, Inc.

Dr. Marango will assume CFO role effective April 25, 2022, succeeding interim CFO Mark Manfredi.
Base salary of $425,000; annual bonus target of 40% of base salary.
Granted option to purchase 397,199 shares, vesting 25% on one-year anniversary and rest over 36 months.
Dr. Marango previously served as SVP, CFO and CBO at Aptose Biosciences.
Severance benefits include lump-sum payments and accelerated vesting upon qualifying termination.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jotin Marango

Chief Financial Officer, Head of Corporate Development

IMA · ImageneBio, Inc.

Effective: 2022-04-25
Filed: April 13, 2022, 7:59 PM ET

appoint Jotin Marango, M.D., Ph.D. as Chief Financial Officer, Head of Corporate Development, effective April 25, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jotin Marango was appointed as Chief Financial Officer, Head of Corporate Development at ImageneBio, Inc..

Action: appointed
Role: Chief Financial Officer, Head of Corporate Development

Exact text from the filing

appoint Jotin Marango, M.D., Ph.D. as Chief Financial Officer, Head of Corporate Development, effective April 25, 2022

View on SEC.gov

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-103598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.